Merck’s Bid Sparks 103% Surge in Cidara Stock on CD388 Breakthrough
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Cidara Therapeutics Inc (ticker: CDTX) is a biotechnology company headquartered in San Diego, California, and listed on the Nasdaq exchange. Established in 2012 and renamed in July 2014, Cidara develops targeted immunotherapies using its proprietary Cloudbreak® platform. This platform generates drug-Fc conjugates (DFCs) by coupling small molecules or peptides to a human antibody fragment, aiming to inhibit disease targets while engaging the immune system.
Corporate Structure and Leadership
Cidara operates with a workforce of 11–50 employees. Its leadership team includes Jeff Stein, Ph.D., President and Chief Executive Officer, and James Merson, Ph.D., Chief Virology Officer. Dr. Merson has over 30 years of research and development experience in antivirals, vaccines, and immuno-oncology from firms such as Pfizer and Janssen. The company maintains research and development facilities in San Diego and collaborates with academic and government agencies.
Biotechnology by Louis Reed
Recent Developments and News
On November 13, 2025, Cidara announced an agreement to be acquired by Merck. According to the agreement, Merck will integrate Cidara’s Cloudbreak platform and lead DFC candidate, CD388, into its global development and commercialization network.
In October 2025, the U.S. Food and Drug Administration granted Breakthrough Therapy designation to CD388 based on results from the Phase 2b NAVIGATE trial evaluating single-dose influenza prevention in healthy adults. Additionally, the Biomedical Advanced Research and Development Authority (BARDA) awarded Cidara an initial commitment of $58 million, with up to $281 million in additional funding to support manufacturing scale-up and clinical development of CD388.
Between October 20 and October 23, 2025, Cidara presented translational efficacy data from its Phase 2b NAVIGATE study at the European Scientific Working group on Influenza (ESWI) 10th Influenza Conference in Valencia, Spain. These findings informed dose selection for the ongoing Phase 3 ANCHOR trial in high-risk and immunocompromised populations.
Financial and Strategic Analysis
As of November 14, 2025, Cidara’s share price stood at $215.55, reflecting a 103.37% increase intraday on a trading volume of 1,186,564 shares (average volume: 866,718). The company’s market capitalization is approximately $3.34 billion. Cidara reported a net loss of $184.8 million for the trailing twelve months, with diluted EPS of –$11.21. At the end of the most recent quarter, Cidara held $420.0 million in cash and cash equivalents against a debt-to-equity ratio of 0.47%.
| Metric | Value |
|---|---|
| Share Price (Nov 14, 2025) | $215.55 |
| Intraday Change | +103.37% |
| Volume | 1,186,564 |
| Market Capitalization | $3.34 billion |
| TTM Net Income | –$184.8 million |
| TTM Diluted EPS | –$11.21 |
| Cash (mrq) | $420.0 million |
| Debt/Equity (mrq) | 0.47% |
The transaction with Merck is expected to enhance the global reach of CD388 and utilize Merck’s regulatory and commercial infrastructure. Cidara’s antifungal candidate, rezafungin acetate, is approved for treating invasive fungal infections, while its Cloudbreak platform advances multiple preclinical and clinical-stage programs targeting influenza, cancers, and other serious diseases.
Market Position and Industry Context
Cidara operates in the biotechnology sector, specifically within infectious diseases and immuno-oncology. Its DFC approach differentiates from monoclonal antibodies and small-molecule antivirals by combining targeted inhibition with immune engagement. CD388 competes with seasonal influenza vaccines and antiviral prophylactics under development by major pharmaceutical companies. The company’s financial metrics, including a beta of 1.55 and lack of revenue growth, reflect typical early-stage biotech risk profiles. Partnership with Merck and the support from BARDA position Cidara to advance late-stage clinical trials and potential commercial launches in a market with ongoing global demand for improved influenza prevention and antifungal treatments.
tl;dr
Cidara agreed to be acquired by Merck on November 13, 2025, integrating its Cloudbreak platform and lead candidate CD388 into Merck’s development pipeline. In October 2025, the FDA granted Breakthrough Therapy designation to CD388, and BARDA committed up to $339 million for its clinical and manufacturing expansion. The Phase 3 ANCHOR trial is underway in high-risk populations. As of November 14, 2025, shares traded at $215.55 following intraday gains, with a focus on upcoming ANCHOR trial results and the transaction's completion.